Eli Lilly and Company

Chafiq Hamdouchi

Pranab Maiti

Philip Arthur Hipskind

Takako Takakuwa

Concepcion Sanchez-Martinez

Jayana Pankaj Lineswala

Rosanne Bonjouklian

Erik James Hembre, Ii

Jianliang Lu

Carlos Jaramillo Aguado

Sheila Pleite Selgas

Elizabeth Aaron Collins

James Howard Wikel

Stephen A Hitchcock

Chuan Shih

Timothy Alan Shepherd

Wayne A Spitzer

Richard Craig Thompson

Qing Shi

Richard Duane Johnston

Nicholas Paul Camp

Richard E Holmes

Zhaogen Chen

Robert Dean Dally

Mary Margaret Mader

Joseph Michael Gruber

James Lee Toth

Alfonso De Dios

John Richard Morphy

Luisa Maria Martin-Cabrejas

Beatriz Lopez De Uralde Garmendia

Jason Kenneth Myers

Carlos Montero Salgado

Michael John Rupp

Almudena Rubio Esteban

Jesus Ezquerra-Carrera

Miriam Filadelfa Del Prado Catalina

Pramila Kotiyan

Pablo Garcia-Losada

Jose Eugenio De Diego Gomez

Tiecho Li

Anne Reifel Miller

Michal Vieth

Jeremy Schulenberg York

Heather Janelle Barbosa

Miriam Filadelfa Del Prado

The present invention provides a compound of Formula I: wherein Ris methyl, ethyl or cyclopropyl; Ris hydrogen, methyl, or ethyl; Ris methyl or AA; and Ris C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use as a PDE1 inhibitor. 

Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors

The present invention provides a compound of the Formula (I) below: Wherein Ris selected from the group consisting of H, CH, CN, CHCN, C(CH)CN, and F; Ris selected from the group consisting of H, O(C-Calkyl)R, CHCN, and CN; Ris selected from the group consisting of H, OCH, CN, C(CH)CN, and CHCN; Ris selected from the group consisting of H and CH; Ris selected from the group consisting of H, CN, C(CH)CN, OCH, S(O)CH, and C(CH)OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound. 

Isopropyl triazolo pyridine compounds

The present invention provides a compound of the Formula (I) below: wherein Ris selected from the group consisting of H, CH, CN, &#x2014;CHCN, &#x2014;C(CH)CN, F, Cl, and Br; Ris selected from the group consisting of H, &#x2014;O(C1-Calkylene)R4, &#x2014;CHCN, CN, &#x2014;OCH, CF, &#x2014;C(CH)CN, &#x2014;C(CH), &#x2014;S(O)CH, &#x2014;S(O)NH, and &#x2014;OCF; Ris selected from the group consisting of H, CH3, and &#x2014;OCH; and Ris selected from the group consisting of H, &#x2014;C(CH)CN, &#x2014;OCH, &#x2014;S(O)CH, CN, and &#x2014;C(CH)OH; or a pharmaceutical salt thereof, methods of treating type two diabetes using the compound and a process for preparing the compound. 

Phenyl-triazolo-pyridine compounds

The present invention provides compounds of the formula wherein

Triazolo-pyridine compound

A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes. 

Spiropiperidine compounds

The present invention provides a compound of the formula below or a pharmaceutical salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.

1,2,3,4-tetrahydroqinoline derivative useful for the treatment of diabetes

A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. 

Thiazole pyrazolopyrimidines CRF1 receptor antagonists

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases. 

Imidazopyridazine compounds

The present invention provides kinase inhibitors of Formula I. 

Kinase inhibitors

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases. 

The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis 

Benzimidazoles and benzothiazoles as inhibitors of map kinase

Anti-viral compounds

An improved and a new synthetic route for the reparation of spirocyclic C-glycoside compounds having the following general structure are described. ##STR1## Novel derivatives of spirocyclic C-glycoside compounds are also disclosed which may be used as intermediates in the synthesis and evaluation of potential pharmaceutically active materials.

Spirocyclic C-glycosides

Growing community of inventors

Carmel, IN, United States of America

Chafiq Hamdouchi